Myriad Genetics (MYGN) Cash & Equivalents (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Cash & Equivalents data on file, last reported at $124.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $124.4 million, up 35.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $124.4 million (up 35.51% YoY), and the FY2025 annual result was $149.6 million, up 46.09% from the prior year.
• Cash & Equivalents fell to $124.4 million in Q1 2026 per MYGN's latest filing, from $149.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $164.2 million in Q1 2022 and troughed at $53.6 million in Q1 2023.
• A 5-year average of $104.5 million and a median of $102.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 77.89% in 2022, then surged 132.16% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $56.9 million in 2022, then soared by 132.16% to $132.1 million in 2023, then fell by 22.48% to $102.4 million in 2024, then soared by 46.09% to $149.6 million in 2025, then decreased by 16.84% to $124.4 million in 2026.
• Business Quant data shows MYGN's Cash & Equivalents at $124.4 million in Q1 2026, $149.6 million in Q4 2025, and $145.4 million in Q3 2025.